Ziconotide: Side Effects

Important Safety Notice#

Ziconotide (Prialt) carries a BLACK BOX WARNING for severe psychiatric symptoms and neurological impairment. Patients should be monitored frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Ziconotide is contraindicated in patients with a history of psychosis.

Common Side Effects#

The most frequently reported adverse effects from clinical trials include dizziness (up to 47%), nausea (30%), confusion (15-33%), headache (15%), somnolence (17%), abnormal gait (14-16%), and urinary retention (9%). The frequency and severity of adverse effects are dose-related and are significantly reduced with slow titration protocols starting at 2.4 mcg/day.

Serious Adverse Events#

Psychiatric Effects (Black Box Warning)#

Severe psychiatric symptoms including hallucinations (12%), paranoid reactions (3%), delirium (2%), and psychosis (1%) have been reported. These effects may occur at any time during treatment. Patients with a preexisting history of psychosis must not be treated with ziconotide. New-onset psychotic symptoms require immediate discontinuation.

Cognitive Impairment#

Memory impairment, speech disorder, aphasia, and abnormal thinking occur in 7-22% of patients. Cognitive function should be assessed regularly during treatment. These effects are generally reversible after dose reduction or discontinuation.

Rhabdomyolysis#

Elevated creatine kinase (CK) levels occur in approximately 40% of patients. Rare cases of rhabdomyolysis and acute renal failure have been reported. CK levels should be monitored periodically during treatment.

Meningitis#

Cases of meningitis have occurred, which may be related to the intrathecal delivery system or the drug itself. Fever, headache, stiff neck, altered mental status, and CSF pleocytosis should prompt evaluation.

Drug Interactions#

Ziconotide is degraded by peptidases and does not interact with cytochrome P450 enzymes. However, concomitant use of CNS depressants (opioids, benzodiazepines, neuroleptics, sedatives) may increase the risk of CNS-related adverse effects. Intrathecal chemotherapy should not be co-administered.

Contraindications#

Ziconotide is contraindicated in patients with a history of psychosis, hypersensitivity to the drug, and conditions that would impair intrathecal drug delivery. The drug should be used with extreme caution in patients with a history of depression, suicidal ideation, or cognitive impairment.

Safety Profile Context#

Ziconotide belongs to the Pain category of research peptides. Understanding the side effect profile of Ziconotide is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of Ziconotide. Side effect severity and frequency are based on available clinical data.

Dizziness#

Severity: moderate | Frequency: very common

Dizziness is the most frequently reported adverse event, occurring in up to 47% of patients in clinical trials. Usually dose-related and may improve with dose reduction.

Nausea#

Severity: mild | Frequency: very common

Nausea occurs in approximately 30% of patients. Usually manageable with antiemetics and may diminish over time.

Confusion#

Severity: moderate | Frequency: very common

Confusional state reported in 15-33% of patients depending on titration speed. More common with rapid titration.

Headache#

Severity: mild | Frequency: very common

Headache occurs in approximately 15% of patients. May be related to the intrathecal delivery system as well as the drug.

Abnormal gait and ataxia#

Severity: moderate | Frequency: common

Gait disturbance and ataxia affect approximately 14-16% of patients, reflecting cerebellar effects of N-type calcium channel blockade.

Memory impairment#

Severity: moderate | Frequency: common

Cognitive impairment including memory loss reported in 7-22% of patients. Usually reversible upon dose reduction or discontinuation.

Hallucinations and psychosis#

Severity: severe | Frequency: uncommon

Hallucinations (12%), paranoia (3%), and psychosis (1%) reported in clinical trials. Subject to black box warning. May require immediate discontinuation.

Elevated creatine kinase#

Severity: moderate | Frequency: common

Elevations in serum creatine kinase (CK) occur in approximately 40% of patients. Rarely associated with rhabdomyolysis. CK should be monitored.

Contraindications#

The following contraindications have been identified for Ziconotide based on available research and pharmacological considerations:

• History of psychosis (black box contraindication)
• Known hypersensitivity to ziconotide or any formulation components
• Conditions compromising intrathecal drug delivery (e.g., infection at injection site, spinal cord obstruction, uncontrolled bleeding diathesis)

Individuals with any of these conditions should not use Ziconotide without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for Ziconotide:

• CNS depressants (opioids, benzodiazepines, anticonvulsants) may potentiate dizziness, confusion, and somnolence
• Intrathecal chemotherapy agents should not be co-administered due to potential neurotoxicity
• No CYP450-mediated drug interactions expected (ziconotide is degraded by peptidases)

Drug interaction studies for Ziconotide remain limited. Researchers should exercise caution when combining Ziconotide with other compounds and consult relevant pharmacological references.

Related Reading#

• Ziconotide overview and research guide
• Ziconotide dosing protocols
• Ziconotide risks and legal status